Biliary tract cancer (BTC) is rare in the West, but it is relatively high in Asia, including
Korea. Currently used as the standard primary treatment in metastatic or locally advanced BTC
is gemcitabine/platinum combination chemotherapy.There is no standard secondary chemotherapy
recognized after the failure of the gemcitabine/platinum first line treatment. The
investigators try to evaluate role of 5-FU, leucovorin, irinotecan, and oxaliplatin
combination chemotherapy (FOLFIRINOX) for the patients who progressed after
gemcitabine/cisplatin first line chemotherapy.